Genmab — December 2022
-
-
Preliminary activity is reported with an anti-IL-8 monoclonal antibody plus nivolumab in melanoma
Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors
(dailyreporter.esmo.org)
-
Godmorgen
Opdateret status oversigt for det Danske OMX C25 Index fra NordStock fredag d. 9. december - købs- og salgsignaler: https://www.proinvestor.com/boards/107957/ -
Volume på Genmab ADS var vist ekstraordinær høj i går - næsten 1.4 mill. omsat
-
Ret vildt at tænke på at når Epco og Talquetamab bliver godkendte i løbet af næste år, vil der være 8 Genmab udviklede produkter på markedet. Hvad mon bliver nr. 9. Mim8 fra Novo??
-
Enig GB. Det er vildt og imponerende.
-
Positive Early Results of Mim8 Pave Way for Testing in Phase 3 Trials https://hemophilianewstoday.com/news/mim8-well-tolerated-early-study-paving-way-phase-3-hemophilia-a-clinical-trials/
-
-
Exciting responses to bispecific epcoritamab for Richter's transformed CLL, which can be very tricky to treat https://twitter.com/eddie_cliff/status/1601717217082900480?s=61&t=XzZjo9n9cJC0DuYLqTWXUw
-
Godmorgen.
-
'New lease on life' for blood cancer patients as experimental therapy treats 73 PERCENT of patients in global clinical trials
The treatment targets recurring multiple myeloma, a type of blood cancer
More than 30 percent of trial patients saw all traces of their cancer disappear
Talquetamab work as well or better than similar multiple myeloma treatments https://www.dailymail.co.uk/health/article-11522823/New-blood-cancer-therapy-treats-seven-10-patients.html -
Raj Chakraborty
@rajshekharucms
·
11 t
Although I am super excited about teclistamab combinations in earlier lines of therapy, 6.25% fatal AEs 2/2 infection in Dara-Tec-Len is concerning. Need to develop new strategies to mitigate infection risk such that greater efficacy is not neutralized by high tox https://twitter.com/rajshekharucms/status/1601652144410886150 -
oseph Mikhael
@jmikhaelmd
master presenter Ajai Chari presenting Talquetamab a bispecific antibody targeting GPRC5D. Amazing 74% ORR and even more remarkable low infection rates grade 3/4 at 17% and 12%. This is remarkable and may likely be the next bispecific and First GPRC5D available https://twitter.com/jmikhaelmd/status/1601640239877222403 -
Ben Derman
@bdermanmd
·
11 t
Rub some ‘DRT’ on it. MajesTEC-2 with Dara/Len/Tec. ORR 93.5% in a less refractory population with high rates of CR (55%). No data on mrd negativity among the CR population. But definitely makes a case for combination strategies for teclistamabhttps://twitter.com/bdermanmd/status/1601652148151779328
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind